|Other Names||SOM230, SOM 230, UNII-98H1T17066|
|Trade Name||Orphan Drug|
|Effect Expectation||Brain Meningiomas|
|Inhibitor||Small Somatostatin (SST)|
|SST is a Growth Hormone (GH) Inhibited|
|IUPAC Name||[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate|
Treatment with Pasireotide, also known as SOM230, is meant to shrink brain Meningiomas tumor mass.
Many tumor suppressors for NF2 effect primarily brain Schwannoma tumors that are doing damage to different Cranial Nerves. However Meningiomas are issues as well.
Schwannoma tumors damage the nerves they grown on which is dangerous, but as Meningiomas grow larger, they are just as dangerous as they cause pressure on brain matter and result in different brain function issues. Issues developed would be based on the exact location and possibly size of each problematic tumor.